Wikidata entity: Q64672051
Quantities
| P2899 | minimum age | 18 |
| P1132 | number of participants | 4420 |
| P6099 | clinical trial phase | ... | Q42824827 (phase III clinical trial) | phase III clinical trial |
| P17 | country | ... | Q145 (United Kingdom) | United Kingdom |
| P582 | end time | ... | 2021-12-01 | ??? |
| P31 | instance of | ... | Q30612 (clinical trial) | clinical trial |
| P1050 | medical condition | ... | Q467635 (multiple myeloma) | multiple myeloma |
| P4844 | research intervention | ... | Q408524 ((RS)-cyclophosphamide) | (RS)-cyclophosphamide |
| P4844 | research intervention | ... | Q425681 ((RS)-lenalidomide) | (RS)-lenalidomide |
| P4844 | research intervention | ... | Q905901 (vorinostat) | vorinostat |
| P4844 | research intervention | ... | Q2298283 (melphalan) | melphalan |
| P1813 | short name | Monolingualtext | Myeloma XI | ??? |
| P580 | start time | ... | 2010-05-01 | ??? |
| P8363 | study type | ... | Q78089383 (interventional study) | interventional study |
| P1476 | title | Monolingualtext | Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI) | ??? |
| P3098 | ClinicalTrials.gov ID | NCT01554852 |
Why not click here or view trends?
log id: 3909674